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Previous studies indicated that hepatitis C virus core protein influences cellular apoptosis. However, the precise
mechanisms of the effects are not fully understood. Therefore, in this study, we examined the mechanisms of the effects on
cell apoptosis by core protein, using transiently transfected and magnetically collected core-producing HepG2 cells. First, to
elucidate the target site of core protein in the apoptotic pathway, we examined the activation of caspases after anti-Fas
antibody stimulation. Core protein inhibited the apoptotic cascade downstream from caspase 8 and upstream from caspase
3. Next, to clarify more direct mechanisms of this effect, mRNA levels of several bcl-2-related genes were examined. An
RNase protection assay showed that the mRNA of bcl-xl increased in the core-producing cells. We showed that this increase
was mediated by the enhancement of bcl-x promoter activity by core protein through an extracellular-regulated kinase
pathway. These results suggest that core protein inhibits apoptosis at the mitochondria level through augmentation of Bcl-xINTRODUCTION
Hepatitis C virus (HCV) is a positive-stranded RNA
virus and a major causative agent of chronic hepatitis,
cirrhosis, and hepatocellular carcinoma (Kuo et al., 1989;
Saito et al., 1990; Shiratori et al., 1995; Takano et al.,
1995). More than 170 million persons are chronically
infected with HCV worldwide (WHO, 1998). The HCV
genome contains a large open reading frame encoding a
polyprotein precursor of 3010–3033 amino acids and an
untranslated region at the 5 and 3 ends of the genome.
The putative organization of the HCV genome includes
the 5 untranslated region, three or four structural pro-
teins (core, E1, and E2/p7), six nonstructural (NS) pro-
teins (NS2, NS3, NS4A, NS4B, NS5A, and NS5B), and the
3 untranslated region (Choo et al., 1991; Hijikata et al.,
1991; Grakoui et al., 1993).
Apoptotic cell death with viral infection can be induced
by the host immune response or by viral proteins, and
apoptosis is considered to be a common pathway of
virus clearance. On the other hand, viruses encode pro-
teins that suppress apoptosis and escape this clearance
mechanism (reviewed by White, 1996). CrmA, a cowpox
virus genome product, encodes a protease inhibitor of
the caspase family and prevents apoptosis by tumor
necrosis factor  (TNF-) (Beidler et al., 1995), and ade-
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84novirus E1B and human papilloma virus E6 protein sup-
press p53-dependent apoptosis by binding and inactivat-
ing p53 function (Scheffner et al., 1990). These alterations
in cell survival contribute to the establishment of persis-
tent infection and the pathogenesis of a number of dis-
eases including viral oncogenesis (Thompson, 1995; Ru-
din and Thompson, 1997).
In the case of HCV infection, previous studies demon-
strated controversial phenomena concerning apoptosis.
There are several studies indicating that core protein
suppresses apoptosis mediated by cisplatin, c-myc,
TNF-, or the Fas signaling pathway (Ray et al., 1996,
1998; Marusawa et al., 1999; Machida et al., 2001), while
other studies showed that core protein sensitizes Fas-,
TNF--, or serum starvation-induced apoptosis (Ruggieri
et al., 1997; Zhu et al., 1998, 2001; Honda et al., 2000;
Hahn et al., 2000). However, the precise mechanisms of
the effects of core protein on the apoptotic pathway are
not fully understood.
Therefore, in this study, using a magnetic concentra-
tion system for transiently transfected cells, we investi-
gated the effects of the core protein on the apoptotic
pathway.
RESULTS
Caspase-3 activation was suppressed by core protein
The binding of Fas ligand to Fas results in the activa-
tion of the caspase cascade. To determine the target siteexpression, resulting in an inhibition of caspase 3 activatio
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gulated kinase.
where the core protein affects the apoptotic cascade, the
activation of caspases, including procaspase-8, pro-n. © 2
ular-re
caspase-3, and procaspase-7, in the core-producing
HepG2 cells after anti-agonistic Fas antibody treatment
was examined by Western blotting. These forms are
converted into active subunits during activation. Thus,
decreases in the densities of the bands for pro-
caspase-8, -3, or -7 on Western blotting indicate activa-
tion of the respective caspase. Activation of the effector
caspases 3 and 7 was diminished in the core-producing
HepG2 cells compared with activation in the control cells
(Fig. 1). However, activation of the initiator caspase 8
was almost the same, or rather stronger, in the core-
producing HepG2 cells as in the control cells (Fig. 1).
Therefore, core protein was considered to inhibit apo-
ptosis downstream from caspase 8 and upstream from
caspase 3 in the apoptotic pathway.
Core protein enhances the expression of bcl-xl mRNA
and Bcl-xL protein
In hepatocytes, Bcl-2 members have been reported to
act as selective links between specific upstream signals,
such as caspase 8, and downstream death effectors,
such as caspase 3 (Adams and Cory, 1998), and to
protect the liver from Fas-induced apoptosis (Lacronique
et al., 1996). Therefore, we examined the amounts of
mRNA of several Bcl-2-related genes, including bcl-xl,
bcl-xs, bfl1, bik, bak, bax, bcl2, and mcl1 in the core-
producing HepG2 cells by using an RNase protection
assay. In pCXN2-core-transfected HepG2 cells, the
mRNA level of bcl-xl, which is known to inhibit apoptosis,
was increased after transfection, and mcl1, which is also
known to inhibit apoptosis, was also slightly increased
20 and 25 h after transfection (Fig. 2). However, none of
the other members of the bcl family tested was signifi-
cantly affected by core protein expression (Fig. 2). The
mRNA levels of GAPDH and L32, which were investi-
gated as internal controls at the same time, were also
not changed. In addition, the transfection of the empty
vector did not affect any of the genes investigated.
To confirm the enhanced expression of the Bcl-xL
FIG. 1. Core protein suppresses procaspase-3 activation after Fas
stimulation. HepG2 cells were transfected with pCXN2 or pCXN2-core
with pMACS Kk for 24 h. After magnetic concentration, cells were
treated with anti-Fas and CHX for 0 or 12 h. Then, the cells were
collected and resolved by sodium dodecyl sulfate–polyacrylamide gel
electrophoresis and immunoblotted with the indicated antibodies.
FIG. 2. Core protein enhances the expression of bcl-xl mRNA. RNase protection assays with specific probes for bcl-xl, bcl-xs, bfl1, bik, bak, bax,
bcl2, and mcl1 genes were performed by using 10 g total RNA extracted from HepG2 cells after 0, 5, 10, 15, 20, and 25 h of transient transfection
with 3 g of pCXN2-core. As internal controls, the mRNA levels of a ribosomal protein (L32) and GAPDH were simultaneously analyzed. As a control,
the RNA extracted from the cells transfected with the empty vector which were collected 0, 10, or 20 h after transfection was also examined. To identify
the protected bands, the probe without RNase treatment was also applied as a positive control (p.c.). The nomenclature was from the supplier’s kit.
Each probe band migrates slower than its protected band due to the nonhomologous flanking sequences transcribed along with the probe that is
not protected by mRNA. n.c. means negative control using yeast tRNAs which were not protected. Similar results were obtained in another set of
independent experiments.
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protein by core protein, Western blotting was performed.
Bcl-xL expression was enhanced in the core-producing
HepG2 cells compared with the control cells (Fig. 3). Bcl-2
expression was detected in HeLa cells used as a control,
but not in HepG2 cells, consistent with previous reports
(You et al., 1999). Bax expression was not changed in the
core-producing cells compared with that in the control cells
(Fig. 3). Therefore, the increase of Bcl-xL protein expression
in the core-producing cells was considered to contribute to
the inhibition of apoptosis by core protein.
Transactivation of bcl-x promoter by core protein
To determine the effect of core protein on bcl-x pro-
moter activity, HepG2 cells were cotransfected with each
of seven HCV protein expression plasmids and a re-
porter plasmid (pGL2 (848)) containing an 848-bp seg-
ment of the 5 flanking region of the bcl-x gene. Of all the
HCV proteins investigated, only core protein transacti-
vated bcl-x promoter activity. The relative firefly luciferase
activity of pCXN2-core transfected cell lysate was 2.4 0.6
(mean SD) times higher than that of pCXN2 control vector
transfected cell lysates (Fig. 5). This enhancement occurred
in a dose-dependent manner (Fig. 4).
To confirm the similar effects of the core protein on the
bcl-x promoter activity and Bcl-xL protein expression in
the presence of its downstream E1 and E2 envelope
proteins, the HCV structural protein expression vector
pCXN2-HCV-S was cloned and similar experiments were
performed. As shown in Figs. 4C and 4D, core protein
transactivated bcl-x promoter activity and increased the
expression of the Bcl-xL protein in proportion to the
amount of core protein even in the presence of the
envelope proteins.
NF-B activation is not involved in the transactivation
of the bcl-x promoter by core protein in HepG2 cells
Since core protein activates NF-B-associated signal-
ing (Marusawa et al., 1999; You et al., 1999; Kato et al.,
2000) and an up-regulated expression of Bcl-x was re-
ported to be partly mediated by NF-B signaling (Tsuka-
hara et al., 1999; Tamatani et al., 1999; Lee et al., 1999;
Chen et al., 2000), we investigated whether transactiva-
tion of the bcl-x promoter by core protein in HepG2 cells
was also mediated by NF-B signaling. A deletion con-
struct, pGL2 (822), which lacked the NF-B site com-
pared with pGL2 (848), was used for the luciferase assay.
However, this construct also responded to core protein
significantly (Fig. 5A). Furthermore, a mutated NF-B-luc
plasmid, pGLBM, which was the same length as pGL2
(848), but had a CC-to-GG mutation at positions 841
and 840 within the NF-B motif, exhibited similar en-
hancement of core-induced transactivation as observed
with pGL2 (848) (Fig. 5A).
Next, we examined whether blocking of the NF-B
pathway affects core protein-induced transactivation of
bcl-xl by using a superrepressor form of IB mutant
(IBM). IBM, which specifically suppresses NF-B
activity, contains serine to alanine mutations at residues
32 and 36; these abolish sites of phosphorylation by IB
kinase. This IBM expression vector and pCXN2-core
were cotransfected into HepG2 cells along with pGL2
(848) or pNFB-luc, a synthetic promoter that contains
tandem repeats of the binding sites for NF-B linked with
the luciferase gene. The elevated luciferase activity from
pNFB-luc in response to core protein was markedly
suppressed by IBM, but not from pGL2 (848) (Fig. 5B).
These results suggest that the NF-B site located in the
bcl-x promoter region is not involved in the core protein-
induced transactivation of bcl-x in HepG2 cells.
Mapping of core-responsive regions of the bcl-x
promoter
To examine the responsible sites for core-induced
transactivation of bcl-x promoter, a series of luciferase
reporter constructs with several fragments of promoters
of different lengths was prepared and transiently trans-
fected into HepG2 cells along with core expression plas-
mid or control plasmid. Both the basal and the core-
response luciferase activities were markedly reduced
when using pGL2 (197) compared with the results of
other constructs (Fig. 6). These results suggested that
the bases from 198 to 255 in the bcl-x promoter form
one of the major responsive elements of the basal and
core-induced transactivation of bcl-x promoter activity.
The ERK1/2-mediated pathway was involved in the
bcl-x promoter activity
Since we previously showed that core protein acti-
vates not only the NF-B pathway but also the serum
FIG. 3. Core protein enhances the expression of Bcl-xL protein. Western
blot analysis of Bcl-xL, Bcl2, Bax, core, and actin expression was per-
formed using magnetically concentrated HepG2 cell extracts transiently
transfected with pCXN2 (control) or pCXN2-core (core). The cells were
collected 36 h after transfection. HeLa cell extracts were used as a control.
Specific protein bands are indicated by arrows. Similar results were
obtained in another set of independent experiments.
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response element (SRE)-associated pathway (Tsuchi-
hara et al., 1999; Kato et al., 2000; Aoki et al., 2000) and
the activity of transcription factors associated with the
SRE pathway is regulated partly via extracellular signal-
regulated kinases (ERK), we determined the effect of
PD98059, an inhibitor of ERK1/ERK2 activation, on bcl-x
promoter activity. This inhibitor significantly reduced both
the basal level and enhancement of the activity of the
promoter by core protein (Fig. 7). Therefore, the ERK1/2-
mediated pathway was considered to be involved in the
activation of the bcl-x promoter activity at least in hepa-
tocytes.
Core protein inhibits DNA fragmentation after
induction of apoptosis via bcl-xl
To determine whether core protein actually down-regu-
lates apoptosis and whether Bcl-xL expression is respon-
sible for the effects, we performed a DNA fragmentation
assay using the magnetically concentrated core-producing
HepG2 cells and bcl-x antisense oligonucleotide targeted
to the initiation codon of the bcl-x gene. As shown in Fig.
8A, core-producing cells reduced the DNA fragmentation
compared with the control cells after induction of apoptosis.
This effect was reversed by the existence of the bcl-x
antisense oligonucleotide, but not the sense oligonucleo-
tide. Western blotting revealed that antisense treatment
actually reduced the Bcl-xL expression. These results sug-
gested that core protein reduced the apoptotic activities via
the Bcl-xL expression.
DISCUSSION
In this study, we demonstrated that HCV core protein
inhibits apoptosis downstream from caspase 8 and up-
stream from caspase 3. We also showed that core pro-
tein transactivates bcl-x promoter activity, and this may
be one of the mechanisms inhibiting apoptosis mediated
by Fas in HepG2 cells.
There are contradictory data about the effects of the
core protein on apoptosis signals. As reported, the con-
tradiction may be caused by the use of clonally selected,
FIG. 4. Transactivation of the bcl-x promoter by core protein. (A) Approximately 4 105 HepG2 cells were cotransfected with 0.49 g of pGL2 (848),
0.01 g of pRL-TK, and 0.3 g of pCXN2 or various types of the indicated expression plasmids. Thirty-six hours after transfection, luciferase assays
were carried out with the PicaGene dual sea pansy system. Firefly luciferase activity and sea pansy luciferase activity were measured as relative light
units. Firefly luciferase activity was normalized for transfection efficiency based on sea pansy luciferase activity. The results are expressed by taking
the luciferase activity of pCXN2-transfected control cell lysate as 1. The data represent the mean  the standard deviation of three independent
experiments. * P  0.05 vs pCXN2. (B) Approximately 4  105 HepG2 cells were cotransfected with 0.49 g of pGL2 (848), 0.01 g of pRL-TK, and
indicated amounts of pCXN2-core. Total amounts of transfected DNA were adjusted up to 0.8 g by adding pCXN2 control vector. Luciferase activities
were measured as described for part (A). * P  0.05 vs pCXN2. (C) 4  105 HepG2 cells were cotransfected with 0.49 g of pGL2 (848), 0.01 g of
pRL-TK, and 0.3 g of pCXN2 or pCXN2-HCV-S. Luciferase activities were measured as described for part (A). * P  0.05. (D) Western blot analysis
of Bcl-xL and core expression was performed using magnetically concentrated HepG2 cell extracts transiently transfected with pCXN2, pCXN2-core,
or pCXN2-HCV-S. The cells were collected 36 h after transfection. n.s. means nonspecific band to indicate that the same amount of protein was
applied to each lane.
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permanent transfectant cells, which differ in their char-
acteristic responses from parental cell lines (Marusawa
et al., 1999). Thus, to exclude the chance of selecting
particular cells, we used magnetically concentrated cells
after transient transfection. In this study, we showed that
in magnetically concentrated core-producing HepG2
cells, activation of procaspase-3 mediated by Fas, but
not procaspase-8, was inhibited compared with activa-
tion in the control cells. Therefore, core protein inhibited
apoptosis downstream from caspase 8 and upstream
from caspase 3 in the apoptotic pathway.
Although diverse effects of core protein on apoptosis
have been reported, the underlying mechanisms are not
fully understood. Previous studies showed that hepato-
cytes resemble type II cell lines, in which Fas-induced
death is dependent on mitochondria (Scaffidi et al.,
1998), and that bcl-2 members act as a selective linkers
between upstream signals and downstream death effec-
tors (Lacronique et al., 1996; Adams and Cory, 1998). In
this study, using an RNase protection assay and Western
blotting, we showed that not only bcl-xl mRNA, but also
Bcl-xL protein, was increased in the core-producing
HepG2 cells. As Bcl-xL is known to efficiently block the
cleavage-mediated activation of procaspase-3, a critical
downstream effector caspase in the apoptotic pathway
(Chinnaiyan et al., 1996; Erhardt and Cooper, 1996;
Shimizu et al., 1996), the core-producing HepG2 cells
were considered to inhibit cleavage-mediated activation
of procaspase-3, through enhanced expression of Bcl-xL
protein.
Recently, NF-B was reported to be an inducer of bcl-xl
in lymphocytes and primary neurons stimulated by CD40,
TNF, or human T-cell leukemia virus type 1 Tax protein
(Tsukahara et al., 1999; Lee et al., 1999; Tamatani et al.,
1999; Chen et al., 2000). However, although core protein
activates the NF-B pathway (Marusawa et al., 1999; You
et al., 1999; Kato et al., 2000; Yoshida et al., 2001), the
enhanced expression of Bcl-xL by core protein was not
dependent on the NF-B site in the bcl-xl promoter in this
study (Fig. 4). The difference in the data may be ex-
plained by the fact that the regulation of bcl-xl expression
appears to be quite complex and the contribution of
NF-B to this process may depend on cell type or acti-
vating stimuli. In fact, other studies failed to reveal alter-
ations in bcl-xl transcript levels by NF-B activation
(Wang et al., 1998; Wu et al., 1998; Grumont et al., 1999).
On the contrary, it was reported that NF-B activation
was a negative regulator of Bcl-xL in double-positive
thymocytes (Hettmann et al., 1999). Thus, further study is
needed to clarify the fine regulation of Bcl-xL expression
by NF-B.
Other transcription factors, such as Stat 1, Stat 5, and
Ets 2, are also implicated in the regulation of bcl-xl
expression (Fujio et al., 1997; Sevilla et al., 1999; So-
colovsky et al., 1999), and multiple binding sites for tran-
scriptional factors were identified in the bcl-x promoter
(Grillot et al., 1997; Grad et al., 2000). In this study, we
found that the bases from 198 to 255 in the bcl-x
promoter form one of the responsive elements of the
basal- and core-induced transactivation of bcl-x pro-
moter activity in hepatocytes (Fig. 6). Although an elec-
trophoretic mobility shift assay revealed that nuclear
protein actually binds to this region (data not shown), no
serum response element was located within this region
by our computer analysis. However, the present studies
showed that PD98059, an inhibitor of ERK1/ERK2 activa-
tion, significantly reduced both the basal and the core-
mediated activation of the bcl-x promoter (Fig. 7). These
results were consistent with the recent report that the
ERK signaling pathway regulates Bcl-xL expression in
FIG. 5. NF-B activation was not involved in transactivation of the
bcl-x promoter by core protein in HepG2 cells. (A) HepG2 cells were
transfected with 0.01 g of pRL-TK, 0.3 g of pCXN2-core or pCXN2,
and 0.49 g of the indicated reporter plasmids. pGL2 (822) deletes the
NF-B site. pGL2BM contained mutations within the NF-B site as
described under Materials and Methods. Luciferase assays were mea-
sured as described in the legend for Fig. 4A. The results are expressed
by taking the luciferase activity from pGL2 (848) of pCXN2-transfected
control cell lysate as 1. Data represent the mean  the standard
deviation of three independent experiments. * P  0.05 vs pCXN2. (B)
HepG2 cells were transfected with 0.49 g of pGL2 (848) or NFB-luc,
0.01 g of pRL-TK, and 0.3 g of the indicated expression plasmids.
Total DNA amounts were adjusted by adding pCXN2 to 1.1 g. Thirty-six
hours after transfection, luciferase assays were carried out as de-
scribed in the legend for Fig. 4A. TNF- (10 ng/ml) was added 24 h
before the luciferase assays if necessary. The data represent the
mean  the standard deviation of three independent experiments.
* P  0.05 vs pCXN2.
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pancreatic cancer cells (Boucher et al., 2000). Therefore,
to clarify precise mechanisms of the activation of this
promoter activity, protein(s) binding to this region must
be identified in the future.
Our findings do not exclude the possibility that the
activation of NF-B by core protein may lead to suppres-
sion of apoptosis, since NF-B is known to induce ex-
pression of IAP families that inhibit apoptosis at various
points in the apoptotic cascade (Deveraux and Reed,
1999). Although we could not detect the expression of
c-IAP-2 protein in HepG2 cells (data not shown), there
remains a possibility that other IAP families may also be
involved in the inhibition of apoptosis by core protein
through NF-B activation.
The Fas system is known to play an important role in
liver cell injury by HCV and in the clearance of viruses
(Cerny and Chisari, 1999). The ability of core protein to
inhibit the Fas-mediated apoptotic pathway by up-regu-
lation of Bcl-xL expression may provide a selective ad-
vantage for evasion of host antiviral defense mecha-
nisms. Previous immunohistochemical analysis actually
revealed that Bcl-xL expression in hepatocytes was ele-
vated in livers with HCV-related cirrhosis (Frommel et al.,
1999). Recently, it was reported that the expression of
Bcl-xL is high in hepatocellular carcinoma (Takehara et
al., 2001). In addition, core protein was reported to in-
duce hepatocellular carcinoma in transgenic mice
(Moriya et al., 1998). Therefore, it is possible that the
selection of Bcl-xL-expressing cells by their capacity to
inhibit apoptosis could account for the development of
hepatocellular carcinoma in hepatitis C patients.
In conclusion, we demonstrated that HCV core protein
enhanced the expression of Bcl-xL, and this was associ-
ated with the inhibition of procaspase-3 activation. Core
protein-mediated Bcl-xL induction may be one of the
mechanisms underlying its inhibition of apoptosis, which
might contribute to the pathogenesis of HCV.
MATERIALS AND METHODS
Cell lines
Human hepatoblastoma cells (HepG2) and human cer-
vical carcinoma cells (HeLa) were obtained from the
Riken Cell Bank (Tsukuba Science City, Japan) and main-
FIG. 6. Mapping of core-responsive regions in the bcl-x promoter. (A) HepG2 cells were transfected with 0.01 g of pRL-TK, 0.3 g of pCXN2-core or
pCXN2, and 0.49 g of a series of reporter plasmids with several fragments of different lengths of 5-deleted bcl-x promoters. Luciferase activities were
measured as described in the legend for Fig. 4A. The results are expressed by taking the luciferase activity from pGL2 (848) and pCXN2-transfected control
cell lysate as 1. The data represent the mean  the standard deviation of three independent experiments. Constructs of the reporter plasmids used are
schematically illustrated in the left panel. Fragments of the 5 flanking region of the bcl-x gene are represented by heavy lines, and the number at the 5
end of each construct indicates the 5-most end base positions from the translation initiation codon of the bcl-x gene.
FIG. 7. The ERK1/2-mediated pathway was involved in the activation
of bcl-x promoter activity by core protein. HepG2 cells were transfected
with 0.49 g of pGL2 (848), 0.01 g of pRL-TK, and 0.3 g of the
indicated expression plasmids. Thirty-six hours after transfection, lu-
ciferase assays were carried out as described in the legend to Fig. 4A.
PD98059, an inhibitor of ERK1/ERK2 activation (50 mol/L), was added
24 h before the luciferase assays if necessary. Data represent the
mean  the standard deviation of at least three independent experi-
ments. * P  0.05.
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tained in Dulbecco’s modified Eagle’s medium (Gibco
BRL, Gaithersburg, MD) supplemented with 10% heat-
inactivated fetal bovine serum.
Expression plasmids and reporter plasmids
The expression plasmids pCXN2-core, NS2, NS3, NS4A,
NS4B, NS5A, and NS5B containing the respective HCV
genomic regions, driven by a -actin-based CAG promoter,
were constructed as described previously (Kato et al.,
2000). A control plasmid (pCXN2) was also used. The ex-
pression plasmid pCXN2-HCV-S, containing the HCV struc-
tural regions (core, E1, E2, and p7), was newly constructed
by site-specific recombination-based cloning technology
(Gateway Cloning Technology; Life Technologies, Rock-
ville, MD) according to the manufacturer’s instructions.
Briefly, pCV-J4L6S, containing a full-length infectious
HCV clone, was kindly provided by Professor Bukh
(Yanagi et al., 1998). Using this clone as a template,
structural regions were amplified with the primers
(5-GGGGACAAGTTTGTACAAAAAAGCAGGCTGCACCA-
TGAGCACGAATCCTAAAC-3 and 5-GGGGACCACTT-
TGTACAAGAAAGCTGGGTCAGGCGTAAGCTCGTGGTGG-
TAACG-3). Primers contained extra bases for recombina-
tion (underlined). The PCR products were cloned into
pDONR201 (Life Technologies) and then cloned into pCXN2
destination vector by recombination protein. The pCXN2
destination vector was constructed by inserting a Gateway
conversion cassette into the cloning site of the pCXN2
vector.
An expression vector of the superrepressor form of
IBM containing serine to alanine mutations at resi-
dues 32 and 36, which specifically suppress NF-B ac-
tivity, was kindly provided by Dr. Hiroshi Suzuki (Suzuki et
al., 1999).
The following vectors containing the Photinus pyralis
(firefly) luciferase reporter gene driven by a basic promoter
element (TATA box) plus an inducible cis-enhancer element
were utilized as reporter plasmids. The bcl-x promoter-
driven luciferase reporter plasmids pGL2 (848) and pGL2
(822), which contained DNA fragments of the bcl-x pro-
moter at the base positions of 848 to 75 and 822 to
75 from the translation initiation ATG of the mouse bcl-x
gene, respectively, were kindly provided by Dr. Mari Kan-
nagi (Tsukahara et al., 1999), who also provided pGLkBM, a
mutant of pGL2 (848) carrying CC-to-GG mutations at po-
sitions841 and840 within the NF-B-binding site. pGL2
(638), pGL2 (458), pGL2 (408), pGL2 (278), pGL2 (255), and
pGL2 (197) were newly generated by inserting DNA frag-
ments of the bcl-x promoter at the base positions 638,
458, 408, 278, 255, and 75 from the translational
initiation ATG of the bcl-x gene, respectively, into the pGL2
basic vector containing a luciferase reporter gene (Pro-
mega, Madison, WI). These DNA fragments were amplified
by PCR using pGL2 (848) as a template and six sense
primers (5-CCGCTCGAGTGGTCCATGGAGGAACCAGG-3,
5-CCGCTCGAGCTATGATACAAAAGACCTTCC-3, 5-CC-
GCTCGAGAGATTTGAATGTAGGTGG-3, 5-CCGCTCGAGT-
GGTCCTTTCAATTTGACTTC-3, 5-CCGCTCGAGTGA-
AGTCCCTTAGAACCCG-3, 5-CCGCTCGAGGGTACCTG-
GAGGAATATTG-3) and one antisense primer (5-CCGCTC-
GAGGCGATTCTCTTCCAGGATC-3). Gene integration was
confirmed by DNA sequencing. A synthetic promoter that
contains tandem repeats of the binding sites for NF-B
(pNFB-Luc) was purchased from Stratagene (La Jolla, CA).
To check transfection efficiency, pRL-TK, a control plasmid
that expresses Renilla reniformis (sea pansy) luciferase
driven by herpes simplex virus thymidine kinase (Toyo Ink,
Tokyo, Japan), was used.
Concentration of transiently transfected cells and
immunoblotting
We used the MACSelect system (Myltenyi Biotec, Ber-
gisch Gladbach, Germany) for specific concentration of
transiently DNA-transfected cells from the heteroge-
neous cell population as described previously (Goto et
al., 2001). Plasmid-transfected cells were concentrated
FIG. 8. Core protein inhibits DNA fragmentation after induction of
apoptosis via bcl-x. (A) HepG2 cells were transfected with pCXN2 or
pCXN2-core with pMACS Kk for 24 h, with or without bcl-x antisense or
sense oligonucleotide transfection. After magnetic concentration, cells
were treated with anti-Fas and CHX for 12 h. Then genomic DNA was
extracted and DNA fragments were amplified from equal amounts of
DNA as described under Materials and Methods. As an internal con-
trol, the En-2 gene product was also examined. The DNA products
were loaded on a 1.2% agarose/EtBr gel. M means 1-kb ladder. n.c.
means negative control derived from HepG2 cells without induction of
apoptosis. (B) Western blot analysis of Bcl-xL expression was per-
formed using magnetically concentrated HepG2 cell extracts tran-
siently transfected with pCXN2 (vector) or pCXN2-core (core) with or
without bcl-x antisense or sense oligonucleotide transfection. The cells
were collected 36 h after transfection. Cell extracts were normalized for
protein concentration, resolved by sodium dodecyl sulfate–polyacryl-
amide gel electrophoresis, and immunoblotted.
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by magnetic isolation using a specific surface marker, a
truncated mouse H-2Kk molecule, which was expressed
from the cotransfected plasmid, pMACS Kk. Approxi-
mately 107 HepG2 cells were transfected with 3 g of
pCXN2-core or pCXN2 control plasmid, together with 1
g of pMACS Kk. After 24 h, cells were trypsinized and
dispersed by pipetting into single-cell suspensions. The
cells were resuspended with 80 l of micromagnetic
beads conjugated with a monoclonal antibody against
mouse H-2Kk and incubated for 15 min at room temper-
ature. Magnetically labeled cells were recovered by the
magnetic separation column. The transfected cells col-
lected magnetically were treated with anti-agonistic Fas
antibody (CH-11; MBL, Nagoya, Japan) at a final concen-
tration of 10 ng/ml. A minimum of 500 ng/ml of cyclohex-
imide (CHX) was required for anti-Fas-induced apoptosis
in HepG2 cells, as described previously (Marusawa et
al., 1999). Both the detached and attached cells were
collected 0 or 12 h after the start of anti-Fas treatment.
Cell extracts were normalized for protein concentration
with a Micro BCA Protein Assay Reagent Kit (Pierce,
Rockford, IL), resolved by sodium dodecyl sulfate–poly-
acrylamide gel electrophoresis, and immunoblotted as
described previously (Kato et al., 2000). To evaluate
caspase activation, anti-procaspase-8 (MBL), anti-pro-
caspase-3 (Transduction Laboratories, Lexington, KY),
and anti-procaspase-7 (Transduction Laboratories) were
used in this experiment. To evaluate the expression
levels in the cells transfected with pCXN2-core, pCXN2-
HCV-S, or pCXN2, anti-Bcl-xL (Transduction Laborato-
ries), an anti-inhibitor of apoptosis protein (IAP) -2 (Gen-
zyme, Cambridge, MA), anti-Bcl-2 (Santa Cruz, CA), anti-
actin (Chemicon, Temecula, CA), and anti-HCV core
(Austral Biologicals, San Ramon, CA) were used. The
bound antigen was detected using the ECL-plus Western
blotting detection system (Amersham, Pharmacia, Buck-
inghamshire, UK).
RNase protection assay
We analyzed the amounts of bcl-xl, bcl-xs, bfl1, bik,
bak, bax, bcl2, and mcl1 gene mRNAs in HepG2 cells
transiently transfected with pCXN2-core by RNase pro-
tection assay (RPA) with the RPA III kit (Ambion, Austin,
TX) as described previously (Kiefer et al., 1995). Approx-
imately 107 HepG2 cells were transiently transfected with
3 g of pCXN2-core. After 0, 5, 10, 15, or 20 h of incuba-
tion, all the cells were lysed with Isogen solution (Nippon
Gene, Toyama, Japan), and total cellular RNA was ex-
tracted by an acid guanidinium thiocyanate–phenol–
chloroform method according to the manufacturer’s in-
structions. RNA probes used for this assay were synthe-
sized by in vitro transcription with templates included in
an hAPO-2 human apoptosis template set (PharMingen,
San Diego, CA) according to the supplier’s instructions.
The total RNA (10 g) was hybridized with a mixture of
32P-labeled antisense RNA probes (3  105 cpm) over-
night at 56°C in a hybridization buffer and then treated
with RNase A/T1. The resultant protected RNAs were
separated on 5% acrylamide gels with 8 M urea and
visualized by autoradiography. As internal controls, the
mRNA levels of a ribosomal protein (L32) and glycelal-
dehyde-3-phosphate dehydrogenase (GAPDH) were an-
alyzed. As a control, the RNA extracted from the cells
transfected with the empty vector which were collected
0, 10, or 20 h after transfection was also examined. To
identify the protected bands, the probe without RNase
treatment was also applied. The nomenclature was from
the supplier’s kit.
Transient transfection and luciferase assay
To evaluate the ability of core protein to activate the
transcription of bcl-x, transient transfection and a lucif-
erase assay were performed. Approximately 4  105
cells were plated into wells of 6-well tissue culture plates
24 h before transfection. Transfection was performed
using the FuGene6 Transfection Reagent (Boehringer
Mannheim, Mannheim, Germany) according to the man-
ufacturer’s instructions. Unless otherwise specified,
transfection complexes containing 0.8 g of plasmids
(0.49 g of firefly luciferase reporter plasmid, 0.01 g of
pRL-TK, and 0.3 g of pCXN2 or various expression
plasmids) were added to each well of the 6-well plates.
Human recombinant TNF- (10 ng/ml; Pharma Biotech-
nologie Hanover, Hanover, Germany) or PD98059 (50
mol/L; Promega), an inhibitor of extracellular signal-
regulated kinases (ERK1/ERK2), was added 24 h before
the luciferase assays if necessary. Cells were harvested
36 h after transfection, and luciferase assays were car-
ried out with the PicaGene dual sea pansy system (Toyo
Ink). Firefly luciferase activity and sea pansy luciferase
activity were measured as relative light units with a
luminometer (Lumat LB9507, EG&G Berthold, Bad Wild-
bad, Germany). Firefly luciferase activity was normalized
for transfection efficiency based on sea pansy luciferase
activity. All assays were performed at least in triplicate.
Antisense oligonucleotide and transfection
Oligonucleotides with a phosphorothioate backbone
were synthesized (Sawady Co., Tokyo, Japan). The anti-
sense oligonucleotide encodes a sequence complemen-
tary to the human bcl-x translation initiation site and
extending 3 downstream for a total of 18 bases (Take-
hara et al., 2001). A sense oligonucleotide was used as
a control. The sequence of these oligonucleotides was
as follows: antisense sequence, 5-CCGGTTGCTCT-
GAGACAT-3; sense sequence, 5-ATGTCTCAGAGCAAC-
CGG-3.
To enhance cellular uptake, oligonucleotides were de-
livered in the form of complexes with FuGENE6 Trans-
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fection Reagent. Each oligonucleotide was added to the
cellular medium at the concentration of 400 nmol/L.
DNA fragmentation assay
For the semiquantitative analysis of apoptosis, a DNA
fragmentation assay was performed using ApoAlert LM-
PCR Ladder Assay kit (Clontech, Palo Alto, CA) according
to the manufacturers’ instructions. Briefly, using magnet-
ically concentrated HepG2 cells transfected with pCXN2
or pCXN2-core with or without bcl-x antisense or sense
oligonucleotides, apoptosis was induced by Fas stimu-
lation as described. Both the detached and attached
cells were collected 12 h after the start of anti-Fas treat-
ment. From the collected cells, genomic DNA was ex-
tracted. After the adaptor ligation, 100 ng of each adap-
tor-ligated DNA was used as a template for PCR to
amplify the DNA fragments. The PCR conditions were as
follows: incubation for 8 min at 72°C, followed by 24
cycles of 94°C for 1 min and 72°C for 3 min. Then 10 l
of the each reaction was loaded directly on a 1.2% aga-
rose/EtBr gel. To confirm that equal amounts of DNA
were used for PCR, 100 ng of adaptor-ligated DNA and
1m of human En-2 primers provided in the kit for an
internal control was used.
Statistical analysis
The results of assays of luciferase activity were ana-
lyzed using analysis of variance (ANOVA) with a post hoc
Scheffe test (StatView J, Abacus Concepts Inc., Berkeley,
CA). The data represent the mean  SD calculated from
three independent experiments. Differences with a value
of P  0.05 were considered significant.
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